This spectrum consists of isolated hepatic macrovesicular steatosis at one end and nonalcoholic steatohepatitis (NASH) at the other. Hepatic steatosis is present in ~50% of the subjects with HCV.
The presence of macrovesicular steatosis, hepatocyte ballooning, and lobular inflammation on liver biopsy are features of MASH that distinguish MASH from MASLD, which is not associated with these ...
Background: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback